Chloroquine–Primaquine versus Chloroquine Alone to Treat Vivax Malaria in Afghanistan: An Open Randomized Superiority Trial
The DOI matches its Crossref record.
Abstract
Afghanistan’s national guidelines recommend primaquine (PQ) for radical treatment of Plasmodium vivax malaria, but this is rarely implemented because of concerns over potential hemolysis in patients who have G6PD deficiency. Between August 2009 and February 2014, we conducted an open-label, randomized controlled trial of chloroquine (CQ) alone versus chloroquine plus primaquine (0.25 mg base/kg/day for 14 days) (CQ+PQ) in patients aged 6 months and older with microscopy confirmed P. vivax infection. In the CQ+PQ group, G6PD deficiency was excluded by fluorescent spot testing. The primary outcome was P. vivax recurrence assessed by survival analysis over one year follow-up. Of 593 patients enrolled, 570 attended at or after 14 days of follow-up. Plasmodium vivax recurrences occurred in 37 (13.1%) of 282 patients in the CQ+PQ arm versus 86 (29.9%) of 288 in the CQ arm (Cox proportional hazard ratio [HR] 0.37, 95% confidence interval [CI] 0.25–0.54) (intention-to-treat analysis). Protection against recurrence was greater in the first 6 months of follow-up (HR 0.082; 95% CI 0.029–0.23) than later (HR 0.65, 95% CI 0.41–1.03). Five of seven patients requiring hospital admission were considered possible cases of PQ-related hemolysis, and PQ was stopped in a further six; however, in none of these cases did hemoglobin fall by ≥ 2 g/dL or to below 7 g/dL, and genotyping did not detect any cases of Mediterranean variant G6PD deficiency. PQ 0.25 mg/kg/day for 14 days prevents relapse of P. vivax in Afghanistan. Patient visits during the first week may improve adherence. Implementation will require deployment of point-of-care phenotypic tests for G6PD deficiency.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In Ethiopia, the treatment failure rate decreased from 5.6% with CQ to 0.75% with CQ–PQ [32], and studies in Thailand and Afghanistan also reported lower recurrence rates with CQ–PQ compared to CQ alone [36, 37].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 3
- John, 2012, Primaquine radical cure of Plasmodium vivax: a critical review of the literature, 11, 280
- Price, 2014, Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis, 14, 982
- Cheng, 2015, Systematic review of sub-microscopic P. vivax infections: prevalence and determining factors, 9, e3413
Cited by
Getu, E., Biruksew, A., Eshetu, T., Abamecha, A., Assefa, D. G., Mohammed, H., Wuletaw, Y., Tasew, G., Tollera, G., Hailu, M., et al. (2025) · Malaria Journal · doi:10.1186/s12936-025-05446-y · Cited by 4
Metadata
- Authors
- Awab, G. R., Imwong, M., Bancone, G., Jeeyapant, A., Day, N. P. J., White, N. J., & Woodrow, C. J.
- Venue
- The American Journal of Tropical Medicine and Hygiene
- Published
- 2017-12-06
- Volume
- 97
- Issue
- 6
- Pages
- 1782-1787
- ISSN
- 0002-9637
- 1476-1645
- Cited by
- 20
- References
- 0
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Chloroquine–Primaquine versus Chloroquine Alone to Treat Vivax Malaria in Afghanistan: An Open Randomized Superiority Trial. https://app.cochat.ai/papers/10.4269/ajtmh.17-0290
- The paper
- Awab, G. R., Imwong, M., Bancone, G., Jeeyapant, A., Day, N. P. J., White, N. J., & Woodrow, C. J. (2017). Chloroquine–Primaquine versus Chloroquine Alone to Treat Vivax Malaria in Afghanistan: An Open Randomized Superiority Trial. The American Journal of Tropical Medicine and Hygiene. https://doi.org/10.4269/ajtmh.17-0290
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.